bosentan will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonidebudesonide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonide will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bumetanidetadalafil increases effects of bumetanide by pharmacodynamic synergism. tadalafil increases effects of bumetanide by pharmacodynamic synergism. bumetanide intranasaltadalafil increases effects of bumetanide intranasal by pharmacodynamic synergism. tadalafil increases effects of bumetanide intranasal by pharmacodynamic synergism. butalbitalbutalbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Where to Get Prostate Treatment with Tadalafil in NYC?
armodafinil will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. asenapinetadalafil increases effects of asenapine by pharmacodynamic synergism. tadalafil increases effects of asenapine by pharmacodynamic synergism. butalbital will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. candesartantadalafil increases effects of candesartan by pharmacodynamic synergism. tadalafil increases effects of candesartan by pharmacodynamic synergism. captopriltadalafil increases effects of captopril by pharmacodynamic synergism. tadalafil increases effects of captopril by pharmacodynamic synergism. carbamazepinecarbamazepine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For patients with ED, monitor response to tadalafil carefully because of potential for decreased effectiveness. carbamazepine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. carvediloltadalafil increases effects of carvedilol by pharmacodynamic synergism. tadalafil increases effects of carvedilol by pharmacodynamic synergism. cenobamatecenobamate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate. cenobamate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. chlorthalidonetadalafil increases effects of chlorthalidone by pharmacodynamic synergism. tadalafil increases effects of chlorthalidone by pharmacodynamic synergism. cimetidinecimetidine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cimetidine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clevidipinetadalafil increases effects of clevidipine by pharmacodynamic synergism. tadalafil increases effects of clevidipine by pharmacodynamic synergism. clonidinetadalafil increases effects of clonidine by pharmacodynamic synergism. tadalafil increases effects of clonidine by pharmacodynamic synergism. clotrimazoleclotrimazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clotrimazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. conivaptanconivaptan will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. conivaptan will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crizotinibcrizotinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. crizotinib increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crofelemercrofelemer increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. crofelemer increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporinecyclosporine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dabrafenibdabrafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dabrafenib will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Dosage Form, Shelf-Life & Storage Conditions
tadalafil increases effects of azilsartan by pharmacodynamic synergism. benazepriltadalafil increases effects of benazepril by pharmacodynamic synergism. tadalafil increases effects of benazepril by pharmacodynamic synergism. betaxololtadalafil increases effects of betaxolol by pharmacodynamic synergism. tadalafil increases effects of betaxolol by pharmacodynamic synergism. dasatinibdasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dasatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasiroxdeferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasirox will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dexamethasonedexamethasone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dexamethasone will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazemdiltiazem will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of doxazosin by pharmacodynamic synergism. dronedaronedronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. duvelisibduvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate. duvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenzefavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. elagolixelagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider increasing CYP3A substrate dose if needed. elagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust tadalafil dose for PAH; if on Stribild, start tadalafil 20 mg/day; avoid tadalafil when starting Stribild; for ED, a single dose of tadalafil not exceeding 10 mg in 72 hr. enalapriltadalafil increases effects of enalapril by pharmacodynamic synergism. tadalafil increases effects of enalapril by pharmacodynamic synergism. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. eplerenonetadalafil increases effects of eplerenone by pharmacodynamic synergism. tadalafil increases effects of eplerenone by pharmacodynamic synergism.
2. Choose your treatment
atazanaviratazanavir increases levels of tadalafil by decreasing metabolism. atazanavir increases levels of tadalafil by decreasing metabolism. atenololtadalafil increases effects of atenolol by pharmacodynamic synergism. tadalafil increases effects of atenolol by pharmacodynamic synergism. azilsartantadalafil increases effects of azilsartan by pharmacodynamic synergism. eprosartantadalafil increases effects of eprosartan by pharmacodynamic synergism. tadalafil increases effects of eprosartan by pharmacodynamic synergism. eslicarbazepine acetate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. esmololtadalafil increases effects of esmolol by pharmacodynamic synergism.
Patients and methods
bicalutamidebicalutamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bicalutamide will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bisoprololtadalafil increases effects of bisoprolol by pharmacodynamic synergism. tadalafil increases effects of bisoprolol by pharmacodynamic synergism. bosentanbosentan will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tadalafil increases effects of esmolol by pharmacodynamic synergism. ethacrynic acidtadalafil increases effects of ethacrynic acid by pharmacodynamic synergism. tadalafil increases effects of ethacrynic acid by pharmacodynamic synergism. Combination may increase risk of orthostatic hypotension, tachycardia, dizziness and headache. etravirineetravirine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.